Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitazalimab + mFOLFOX in advanced biliary tract cancer
NCT07437287Phase 3Not yet recruiting
- Sponsor
- Unicancer
- Start
- Jul 2026
- Primary completion
- Apr 2030
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of mitazalimab in biliary tract cancer (BTC), sponsored by Unicancer. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
mitazalimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07437287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07437287.